Amerise biosciences Limited has officially notified BSE Limited that it is not required to submit the Annual Secretarial Compliance Report under SEBI regulations, citing specific exemptions based on its financial parameters. The company communicated this development through a formal letter dated 09.04.2026.

Regulatory Exemption Details

The company has claimed exemption under Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. According to this regulation, corporate governance provisions do not apply to listed entities having paid-up equity share capital not exceeding Rs. 10 crores and net worth not exceeding Rs. 25 crores as on the previous financial year.

Amerise Biosciences stated that the Annual Secretarial Compliance Report under Regulation 24A of SEBI (LODR) Amendment Regulations, 2018, read with BSE Circular dated 9th May, 2019, is not applicable to the company due to this exemption.

Financial Parameters Certification

Practicing Company Secretary Daksha Negi has provided certification confirming the company's eligibility for exemption. The certification details the company's financial position across three consecutive financial years:

The certification confirms that both paid-up capital and net worth remained well below the regulatory thresholds throughout the specified period.

Compliance Framework

The exemption specifically relates to Regulation 27(2) of SEBI (LODR) Regulations, 2015, read with Regulation 15(2)(a) of Chapter IV. The practicing company secretary's certificate, issued from Ahmedabad on 08.04.2026, formally validates that these provisions are not mandatory for Amerise Biosciences Limited.

The company, formerly known as Amradeep Industries Limited, operates under CIN L29199GJ1984PLC007195 and has requested BSE to take this exemption status on record. This regulatory communication ensures transparency regarding the company's compliance obligations while maintaining adherence to applicable SEBI guidelines.

Amerise biosciences Limited has filed its quarterly compliance certificate with BSE Limited for the quarter ended 31st March 2026, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated 06.04.2026, demonstrates the company's adherence to mandatory reporting obligations for listed entities.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting on dematerialization activities. Satellite Corporate Services Private Limited, serving as the company's Registrar & Share Transfer Agent, issued the compliance certificate confirming the status of physical share certificate processing during the reporting period.

Dematerialization Status

The certificate confirms that no physical share certificates were received for dematerialization during the quarter ended 31st March 2026. This indicates that all existing shareholders maintained their holdings in electronic format throughout Q4FY26, reflecting the widespread adoption of dematerialized trading among the company's investor base.

Satellite Corporate Services Private Limited, registered as Category-I Registrar to an Issue & Share Transfer Agent with registration number INR000003639, certified compliance with standard dematerialization procedures. The registrar confirmed that securities comprised in certificates are listed on stock exchanges and that proper verification and record-keeping protocols are maintained.

Corporate Information

Amerise Biosciences Limited, formerly known as Amradeep Industries Limited, operates under CIN L29199GJ1984PLC007195. The company is headquartered at 24, Laxmi Chambers, Navjeevan Press Road, opposite Old Gujarat High Court, Ahmedabad-380014. Albert Hines, serving as Director, signed the regulatory submission on behalf of the company.

The filing was simultaneously submitted to National Securities Depository Limited and Central Depository Services (India) Limited, ensuring comprehensive regulatory compliance across all relevant depositories. This quarterly certification process maintains transparency in the dematerialization framework and protects investor interests in electronic trading systems.